{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:46:05Z","timestamp":1787021165565,"version":"build-2736575974"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>As there is a paucity of data comparing outcomes with different dosing regimens of PD-1 inhibitors in relapsed\/refractory Hodgkin lymphoma (R\/R HL), this retrospective analysis was undertaken to compare the efficacy of low-dose nivolumab (fixed at 40 mg) with the standard dose of 3 mg\/kg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Single-center retrospective analysis of patients with R\/R HL who failed at least one salvage regimen and were treated with nivolumab between 2015 and 2023, at either 3 mg\/kg (standard-dose nivolumab [SD-NIV]) or a flat dose of 40 mg (NIV40), both administered once in 2 weeks. Treatment response was assessed with\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled fluorodeoxyglucose-positron emission tomography-computed tomography after four doses of nivolumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      A total of 45 patients were included: 25 received 3 mg\/kg (SD-NIV) and 20 received a flat dose of 40 mg (NIV40). The mean dose of nivolumab administered once in 2 weeks was 2.9 mg\/kg (stable disease 0.31) in the SD-NIV group compared with 0.6 mg\/kg (stable disease 0.10) in the NIV40 group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). Responses after four doses of nivolumab were similar in the SD-NIV versus NIV40 group: complete response (48%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      50%), partial response (12%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      10%), stable disease (20%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      20%), and progressive disease (20%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      20%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .997). Immune-related adverse effects were similar in the two groups (12%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      10%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .790). Two-year event-free survival (EFS) of the whole cohort treated with nivolumab with SD-NIV and NIV40 was 47% and 49.5%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .788). Twenty-two of the 45 patients underwent stem cell transplant (11 from each group), with a 2-year EFS of 90.1% versus 81.8% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .545) in the SD-NIV and NIV40 groups, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Despite the inherent limitations of a retrospective analysis, the data suggests that nivolumab demonstrates biologic efficacy at doses as low as 0.6 mg\/kg. Prospective trials comparing different dosing strategies are clearly warranted; such studies may facilitate approval of biologically active and cost-effective regimens, thereby broadening access to checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00424","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:58:12Z","timestamp":1772225892000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Standard-Dose Versus Low-Dose Nivolumab in Relapsed\/Refractory Hodgkin Lymphoma\u2014A Retrospective Analysis"],"prefix":"10.1200","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-3832","authenticated-orcid":true,"given":"Chirag","family":"Trivedi","sequence":"first","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junita","family":"John","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6493-7546","authenticated-orcid":true,"given":"Sujith","family":"Karumathil","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4045-3496","authenticated-orcid":true,"given":"Sushil","family":"Selvarajan","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4558-7330","authenticated-orcid":true,"given":"Sharon","family":"Lionel","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hephzibah","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Sunny","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Chandramohan","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-2424","authenticated-orcid":true,"given":"Uday","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-8020","authenticated-orcid":true,"given":"Kavitha","family":"Lakshmi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouzia","family":"Nambiatheyil Aboobacker","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-4434","authenticated-orcid":true,"given":"Aby","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-9501","authenticated-orcid":true,"given":"Biju","family":"George","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-2353","authenticated-orcid":true,"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-3370","authenticated-orcid":true,"given":"Anu","family":"Korula","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010334"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02355"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9012"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00648-X"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01015"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-255021"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.1059"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3007-9"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06098-9"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07044-z"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000480"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_319567"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02563-3"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07782-z"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1295"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00730"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100011"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204488"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:33:40Z","timestamp":1772562820000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1200\/GO-25-00424"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00424","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500424"}}